ArticleJACC. Advances2025
PREVENT Risk Score vs the Pooled Cohort Equations in MESA.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The PREVENT Risk Equations and Cardiovascular Prevention in East Asia.Journal of atherosclerosis and thrombosis · 2026Review
- Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care.Cardiology and therapy · 2026Review
- Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohort.American journal of preventive cardiology · 2026Article
- Impact of PREVENT Cardiovascular Risk Equations on Statin Eligibility by Subgroup and Risk Thresholds: A Cross-Sectional Study.Journal of general internal medicine · 2026Article
- Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models.Future cardiology · 2026Review
- Association of Treadmill Exercise Testing Parameters with PREVENT-Estimated Cardiovascular Risk: A Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review.International journal of molecular sciences · 2026Review
- Cardiovascular risk stratification without recalibration: A comparative study of the PREVENT and WHO risk scores in a multiethnic Brazilian cohort.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn 2023, the American Heart Association developed the PREVENT (Predicting Risk of CVD Events) equations to estimate risk of atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
objectivesAssess the comparative performance of PREVENT-ASCVD vs current guideline-recommended Pooled Cohort Equations (PCE). Evaluate the performance of the PREVENT-HF risk algorithm.
methodsIn 6,098 individuals from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, we calculated baseline PCE, and PREVENT predicted 10-year ASCVD event percentages, observed event percentages at 10 years, discordance between observed and expected percentages, discrimination using Harrell's C index, and calibration using mean absolute error.
resultsObserved ASCVD event rate (6.0%) was closer to the predicted PREVENT event rate (5.7%) than the PCE (10.8%). PREVENT was more accurate in women than men (3.3% vs -11.6% discordance between observed and PREVENT predicted ASCVD), nonsmokers compared to smokers (2.4% vs -37.0% discordance), chronic kidney disease stages 3/4 (discordance 3.2%), and those with high social deprivation scores (discordance -5.0%). Forty-two percent of this cohort would be re-classified to a lower ASCVD risk category using the PREVENT equation vs the PCE. PREVENT-HF overestimates HF events by 2.1%, a relative risk overestimation of 62.6%.
conclusionsPREVENT-ASCVD equations demonstrated a more accurate ASCVD risk-prediction stratification than the PCE. PREVENT performs best in women, nonsmokers, those with a greater degree of renal dysfunction, social deprivation, and Black individuals. PREVENT-HF overestimates risk of incident HF in a Multi-Ethnic Study of Atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.